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Is REACH going well? 
Ineke Gubbels-van Hal & Jacques Pelkmans 
 
1.  REACH in ‘still waters’? 
Little is heard these days about REACH, the new EU 
Regulation on the Registration,  Evaluation, 
Authorisation and Restriction of Chemical 
substances.
1 For the general public and non-
specialised EU observers, the ongoing implementation 
of what is perhaps the biggest EU regulation ever 
undertaken appears to be proceeding in serene 
tranquillity. What a contrast with the turmoil and 
hectic debates that raged between mid-2003 and 
December 2006, when this new EU chemicals 
regulation (of some 850 pages) was finally enacted.  
Remember the European Parliament finding itself in 
need of fitness training? The MEPs had to stand up 
and sit down again every time each of the 1,039 
amendments had to be voted on (first reading), and 
this was repeated 350 times in second reading. 
Remember the fierce and widespread lobbying on 
REACH, even before the first preliminary RIA 
(regulatory impact assessment) of May 2003? And the 
drastic adaptation of the proposal and the final RIA 
only 5 months later? Remember the public letter sent 
by three Prime Ministers (of France, Germany and the 
UK) to European Commission President Romano 
Prodi to reconsider REACH? Or the 41(!) RIAs 
published by lobbying groups, countries, regions and 
NGOs, causing an unprecedented intensity of debate 
                                                      
1 Regulation (EC) No  1907/2006 of the European 
Parliament and of the Council of 18  December 2006 
concerning the Registration, Evaluation, Authorisation and 
Restriction of Chemicals (REACH), establishing a 
European Chemicals Agency, amending Directive 
1999/45/EC and repealing Council Regulation (EEC) 
No 793/93 and Commission Regulation (EC) No 1488/94 
as well as Council Directive 76/769/EEC and Commission 
Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 
2000/21/EC. 
on what is a highly technical piece of EU legislation? 
Or the massive hearing in the EP in January 2005, 
with every one of the 1,000 seats of the EP hall (+ 
balcony) occupied the entire day, and many hundreds 
of spectators standing before the monitors in the 
corridors and the EP café? Not to speak of the serious 
concerns of WTO partners like the US or Japan. 
The silence and ‘still waters’ are remarkable. It would 
be more than surprising if such complex and 
controversial EU legislation, with such radical 
features, would enjoy smooth, timely and effective 
implementation. True, implementation might be 
regarded as relatively easy in case of EU regulations 
(and REACH is an EC regulation) compared to 
directives. No long delays of transposition into 
national laws, no preoccupations over divergences of 
interpretation or about ‘gold-plating’ – adding 
additional features for one country’s benefit only. But 
the absence of these headaches does not imply that the 
implementation of REACH is smooth, timely and 
effective. The Regulation has a number of unique 
properties that render implementation exceedingly 
difficult and burdensome. Close observation of the 
current process confirms that proper and timely 
implementation is a very tall order indeed. 
This CEPS Policy Brief discusses the milestones of 
REACH and the difficulties of its implementation in a 
non-technical fashion. Discussing these issues in 
circles beyond the chemical sector is important 
because REACH is not targeted only or even 
primarily at chemical enterprises. Via the value chain 
and the REACH obligations which come with 
different positions in the value chain, REACH 
implementation affects virtually every industry in the 
EU, including imports. And as a consequence of its 
ambitious health, safety and environmental objectives, 
it is of interest to workers, consumers and citizens 
throughout the EU, if not beyond. 
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Section 2 will sketch out the main properties of 
REACH, the ensuing obligations and ECHA, the 
European Chemicals Agency in Helsinki. We attempt 
to do this in a reader-friendly fashion. Section 3 will 
survey the present status as far as observations by 
outsiders make this possible. We shall demonstrate 
that the REACH Regulation suffers from overly 
ambitious deadlines and a number of technical and 
administrative uncertainties that currently show up in 
a higher burden of implementation for companies and 
the ECHA than expected. Section 4 attempts to look 
one or two years ahead and discuss crucial issues for 
this short run. Section 5 comprises some reflections 
on the complicated cost/benefit structure of REACH 
which can only be appreciated when assuming a long-
run perspective. The implementation process affects 
the cost-benefit picture. Section 6 concludes. 
2.  Reminders about REACH and its 
implications 
Two leading objectives of REACH are the promotion 
of EU public health and the environment insofar as 
these are endangered by chemicals, without adversely 
affecting the industry’s competitiveness. Of course, 
before REACH there was already extensive EU 
chemical legislation in place, but this legislation had 
less broad objectives.  
The point of introducing REACH was and is that 
existing legislation suffered from a number of serious 
drawbacks which rendered it insufficiently effective 
and complete, as well as unnecessarily costly (in some 
respects).
2 The greatest drawback was undoubtedly 
that regulation of specific chemicals before REACH 
often lacked risk assessment.
3 The hazards and risks 
associated with numerous chemical substances were 
not known. Nevertheless, certain categories of 
‘dangerous’ chemicals have been identified and 
restricted in use (or forbidden) without or with partial 
knowledge of health and safety properties. Innovation 
suffered from a penalty in that the existing stock of 
chemical substances registered before 1981 had not 
been tested except in cases where severe risks had 
been detected, whereas new, innovative chemical 
substances (after 1981) had to undergo costly risk 
assessment and some form of risk management. For 
the globally competitive European chemical industry, 
such a penalty amounted to a perverse incentive, 
                                                      
2 Readers interested in getting some notion of the heavy-
handed and multi-layered chemicals regulation before 
REACH, spread over more than 40 EU regulations and 
directives, yet without being swamped by technicalities, are 
advised to read Maglia & Rapisarda Sassoon (2000) and 
KPMG (1997). 
3 Risk is the relationship between intrinsic properties of 
chemical substances (hazard) and actual exposure of 
humans or the environment to the substances. 
prompting excessive reliance on existing chemicals 
even though their risks were (often) not known while 
losing promising options to create more effective or 
less risky chemicals. 
The EU swing to REACH at first seemed to be an 
overreaction, based on the precautionary principle 
applied to all chemicals, even though in many cases 
decades of use had not indicated the slightest 
suspicion of a risk to health or environment. However, 
in the end the application of the principle was more 
measured and the system set up turned out to be far 
less hazard-driven.
4  
REACH therefore amounts to a consistent and all-
encompassing system that aims at controlling risks of 
chemical substances in the EU, produced or used in 
quantities above 1 tonne a year. It aims to do so in 
order to serve health, safety and environmental 
objectives while explicitly promoting the 
competitiveness of the EU chemical industry via the 
avoidance of unnecessary costs as well as the 
facilitation of innovation. Since these two types of 
objectives can conflict, it is essential to carefully 
design REACH as a system and its cost/benefit 
structure over time.  
The 3½ year battle in Brussels over REACH boiled 
down to a struggle to maintain the consistency and 
wide coverage of the system (so as to accomplish a 
complete mapping of risks of all substances above 1 
tonne) while containing its costs. We shall not go into 
an assessment of the REACH system in this 
contribution. The present Policy Brief focuses on the 
ongoing implementation of REACH.  
A simplified flowchart on how REACH works is 
provided in Figure 1. It is based on the principles that 
a) only ‘registered’ substances can be produced and 
marketed and b) industry (including importers) – and 
not ECHA or national authorities – is responsible for 
risk assessment. Producers and importers first ‘pre-
register’ all substances they might later ‘register’ with 
technical dossiers
5 before specific deadlines (Figure 
2); this ‘pre-registration’ should have been done by 1 
December 2008.  
                                                      
4 A hazard is only a necessary but not anywhere near a 
sufficient condition for risks to be important enough for 
regulatory action. Proper risk assessment must check the 
dose/response relationship, verify the expected exposure (or 
ranges of it) – which depends normally on use – and only 
then can the risk be determined. Many hazards do not imply 
risks of any importance because the quantities are minute or 
the exposure is next to zero.  
5 These are called ‘phase-in substances’, the ones already 
included on an EU list by 1981. The ones developed after 
1981 and accepted by authorities are called ‘non-phase-in’ 
substances. They have more generous deadlines. Entirely 
new substances innovated now or in future also fall under 
such a regime.  Is REACH going well? | 3 
Figure 1. REACH implementation 
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Figure 2. Implementing REACH: The deadlines 
 
Source: European Commission. 
 
Figure 1 shows that producers/importers should 
classify all substances,
6 address the properties of the 
chemical substance by test reports or other data 
available and write a risk assessment based on an 
exposure scenario (description of expected ‘exposure’ 
to humans and the environment). All this is then 
submitted to ECHA before the relevant deadlines, 
which differ according to suspected risk, as defined by 
tonnage produced or by concerns already known to 
some degree. ECHA will, in close collaboration with 
the Commission and member states, distinguish two 
routes. First and most frequently, if the substance is 
‘registered’, it is considered safe to be used as 
described in the risk assessment. This enables the 
company(ies) to operate in the internal market. 
Second, if concerns remain, the company(ies) cannot 
operate in the internal market. In specific cases, 
substances will be restricted (banned from the market) 
or authorised for a specific period for a specific 
application (under very strict management 
conditions). This is done via separate procedures and 
on the initiative of the member states and other 
stakeholders. 
For the time being, REACH is mainly about 
generating and sharing risk information, little else. For 
a period of no less than 11 years (until 2018), a series 
of deadlines applies, as shown in Figure 2, for a total 
of some 30,000 substances listed by 1981. For the 
production or marketing of chemical substances in 
                                                      
6 Thus not only those produced or imported in quantities of 
over 1 tonne per year. With some 100,000 chemical 
substances already known in 1981, this is absolutely 
essential. 
quantities in excess of 1,000 tonnes/year and some 
dangerous substances, the registration deadline is 30 
November 2010, which is very tight as we shall show 
below. For smaller tonnages, it is respectively 31 May 
2013 and 31 May 2018.  
The ‘chemical safety reports’ (required for substances 
used in quantities of 10 tonnes and higher) are 
demanding. For example, for substances classified as 
dangerous, the exposure scenarios must include 
operational conditions and appropriate risk 
management measures ensuring adequate risk control 
for all identified uses. In order to reduce costs for the 
Agency, other authorities and industry, part of the 
registration should be jointly submitted on the basis of 
cooperation between companies producing or 
marketing identical substances. The pre-registration 
before December 2008 was also meant to bring 
together producers and importers of the same 
substances and to initiate exchange of information 
between all applicants on what substances they were 
interested in. All companies dealing with substance X 
could then find one another and form a SIEF 
(Substance Information Exchange Forum). SIEFs can 
usefully exchange information but must share existing 
vertebrate animal testing data and agree on the 
generation of new test data. It does not take much 
imagination to appreciate that many thousands of 
SIEFs have to be organised in a very short period of 
time. A crucial characteristic of REACH is the 
consistency down (or sometimes, up) the value-chain.  
The chemical industry consists essentially of two 
layers: primary substance producers – such as BASF, 
Bayer, AKZO-Nobel or DuPont – and the extremely 
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‘formulators’ (many thousands of SMEs, plus the 
majors) making intermediate products by blending 
substances and innovating incrementally but 
incessantly. Both layers, but mainly the second one, 
sell to the downstream users and these include 
practically all sectors of industry. This is illustrated in 
Figure 3.  
Figure 3. Chemicals value chain 
 
Downstream users are fully part of REACH. 
Information relating to health, safety and 
environmental properties, risk and risk management 
measures is required to be passed down or up the 
value chain
7 with the help of safety data sheets (SDS). 
SDSs exist since 1991 but for dangerous substances 
only.  
Obviously, downstream users have to make their uses 
known up the value chain so that ‘identified uses’ 
include their applications.
8 Downstream users 
comprise an incredibly diversified and sizeable 
‘group’ of sectors and subsectors, from furniture-
makers or computer manufacturers to ceramics, oil 
derivatives, cars, textiles, paper, shipbuilding, home 
appliances, building products or cosmetics, and 
others. Much of the consternation in the legislative 
preparation of REACH had to do with the concerns 
and uncertainty of downstream users.  
What costs would it imply for them and when would 
they know for what substance(s) over this lengthy 
period of 11 years? What about substitutes, whether 
introduced for cost reasons or due to reduced risks? 
Would these substitutes equally well fit their 
requirements? What about their costs? What if 
                                                      
7 Commercially sensitive information is not required to be 
exchanged. 
8 There are opt-out possibilities but this implies a separate 
chemical safety assessment by the downstream user, if 
above 1 tonne a year. 
formulators would ‘withdraw’ some substances, 
thereby affecting the quality or characteristics of 
intermediate products supplied to downstream users? 
It is these concerns that prompted lobbyists to suggest 
astronomical cost figures in the early phases of 
decision-making in Brussels. It is now clear that these 
suggestions amounted to wild exaggerations, but it is 
nonetheless a matter of some concern to the numerous 
downstream users.  
3.  The present status of REACH 
implementation 
Originally, it was anticipated that ca 30,000 phase-in 
chemicals would require registration during the period 
2010-2018, but the first phase of REACH has shown 
that this figure was a large underestimation. 
The REACH regulation has been in force since 2007. 
The first year was spent on development and 
implementation of the administrative structure and 
guidance. The impact on industry was still limited. 
REACH actually started on 1 June 2008 with half a 
year available for pre-registration for substances 
already present on the EU market (phase-in 
substances). These substances benefit from an 
exemption from registration until 2010, 2013 or 2018, 
depending on the tonnage produced or imported. This 
pre-registration has been less problematic than 
anticipated by the sector. In general, REACH IT, the 
IT system developed to allow pre-registration and 
registration, functioned well. There were, however, 
some accessibility problems due to the very large 
number of pre-registrations (see below). Since 
December 2008, the first execution phase of REACH 
started. SIEFs were set up and the first registrations 
submitted to ECHA. The first deadline for dossier 
submission of December 2010 is now fast 
approaching. New substances on the EU market need 
to be registered immediately and the work on the 
phase-in substances has been initiated. Many 
companies have prepared themselves extensively 
during the last two to three years. The European 
Chemicals Agency (ECHA) in Helsinki has begun to 
function and produced thousands of pages of 
guidance. 
Despite the enormous efforts of various stakeholders, 
however, the ‘REACH world’ is in many cases less 
well accessible than expected. At this moment 
numerous companies are experiencing serious 
problems in their efforts to meet the (first) registration 
deadlines. 
A number of issues related to REACH are set out 
below in order to show the complexity of the situation 
experienced by the chemical industry in Europe. 
REACH has serious consequences for all companies 
Main substance producers 
(e.g. BASF, Bayer, DuPont, 
etc.) 
‘Integrators’, ‘formulators’ 
(SMEs and some majors) 
Downstream users 
(all industry using compounds 
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putting substances, preparations or articles
9 on the EU 
market. The principle is: no data, no market. As noted, 
REACH influences companies that are considered 
typical representatives of the chemical industry, but 
large numbers of companies in other markets and even 
retailers are affected as well. 
Pre-registration 
The pre-registration period was closed on 1 December 
2008. The 30,000 substances used on the EU market 
were expected to result in some 200,000 pre-
registrations. How different it turned out to be. In 
total, 14 times as many, namely 2,750,000 pre-
registrations were submitted to ECHA by 65,000 
companies. The number of substances was an 
unexpected 146,000. Part of the avalanche was caused 
by ambiguities in the legislative text of REACH. 
ECHA issued some guidance on how to read the text 
only in October 2008, barely six weeks before the 
deadline. Pre-registration was considered necessary 
also for re-imported substances, recovered substances, 
monomers in polymers and substances intended to be 
released from articles. This caused a huge surge of 
additional pre-registrations in November 2008. 
Only Representatives 
In order to allow non-EU manufacturers of chemicals 
to influence their own registration and to relieve the 
burden on importers, REACH foresees the 
establishment of ‘Only Representatives’ (ORs). These 
are legal entities within the EU, taking over the 
responsibility of the importers from a non-EU 
manufacturer for compliance with REACH. At this 
moment it is not clear how many entities act as ORs, 
but it is known that some take care of hundreds or 
even thousands of chemicals on behalf of their clients 
(non-EU manufacturers). Among the ORs, one finds 
consultants, legal firms and EU affiliates of non-EU 
producers, but also companies specially set up to deal 
with OR services. ORs had to submit the pre-
registration, keep track of volumes imported and take 
care of the communication in the supply chain.  
The quality and especially knowledge among ORs can 
differ substantially. For pre-registration, not much 
knowledge was necessary, but during the present 
phase of SIEFs, the OR represents its client in 
discussions on substance ‘sameness’ and other 
technical SIEF tasks. Engaging with a low-quality OR 
can endanger compliance with REACH as well as 
continuation of exports to the EU market. The non-EU 
company itself may have limited knowledge of 
                                                      
9 A technical term defined in Art. 3.3 of the Reach 
Regulation as “an object which during production is given a 
special shape, surface or design which determines its 
function to a greater degree than does its chemical 
composition”. 
REACH and will rely on information coming from his 
OR. The ORs are liable for REACH (non-) 
compliance of their non-EU clients, but the awareness 
of their legal position seems less than satisfactory. 
Substance Information Exchange Forum 
The Substance Information Exchange Forum (SIEF) is 
a forum formed of pre-registrants of the same 
substance with the task to assess substance 
‘sameness’, start the sharing of (vertebrate) data and 
reach agreement on Classification and Labelling. 
Many SIEFs have been formed after 1 December 2008 
and are trying to arrange their cooperative tasks. This 
cooperation is a novel element in REACH. 
Competitors are forced to work together and to 
exchange information. The SIEF idea is part of the 
legislative text of REACH, but nowhere is there the 
slightest rule or recommendation for SIEF 
organisation and management. This omission is costly 
and creates much uncertainty. 
The discussions in the SIEF might lead to the 
exchange of confidential business information as well 
as infringement of EU competition law. Companies 
are allowed, if not forced, to share what is necessary 
under REACH, but have to respect Articles 81, EC 
(on prohibited collusion and anti-competitive 
agreements) and 82, EC (on abuse of dominance, 
possibly collectively). Such discussions may lead to 
tricky situations. Larger companies are aware of these 
risks and train their representatives, but SMEs might 
violate competition law without intending to do so. 
CEFIC, the chemical lobby in Brussels, has launched 
an awareness campaign on precisely this danger.  
In some cases the formation of and work in the SIEF 
led by industry run smoothly, but there are failures, 
too. For example, SIEFs may not start at all. Other 
SIEFs have merely communicated a standard inquiry 
letter and are waiting for a formal start. It is not 
surprising to find that competing companies have 
difficulties initiating the process of data-sharing, but 
few anticipated the trepidation or lack of action that 
currently characterise many SIEFs. This is a serious 
problem, because the process needs to be completed 
rapidly, especially for the many substances to be 
registered by December 2010. There are several IT 
tools available to assist the SIEF process, but these are 
not standardised and in some cases are very 
expensive. Therefore, only a limited number of the 
SIEFs use these tools.  
There is a need for standards and for solutions to force 
mal- or non-functioning SIEFs to start, but legal 
instruments to enforce this are lacking. 
Enforcement 
For a large and ambitious legislation like REACH to 
become successful, strict enforcement is critical. Is REACH going well? | 7 
Enforcement is assigned to the national level. National 
authorities (19 countries in September 2009) have 
enacted enforcement rules: they now check imports 
and perform on-site inspections. However, the rules 
and penalties related to violation of REACH differ 
strongly among EU countries. In some, it may lead to 
imprisonment, while in others only financial penalties 
will apply. A forum of ECHA (The Forum), with 
designated national coordinators as its members, 
addresses enforcement, but is only endowed with 
advisory, coordinating powers. The Forum has 
published and initiated REACH-EN-FORCE-1, the 
first enforcement project concentrating on pre-
registration, registration and safety datasheets.  
Registration 
By September 2009, ECHA had received some 1,200 
registration dossiers (half of these on intermediates). 
These dossiers first undergo a completeness check 
(this has left over ca 500 dossiers) and in some cases 
they might be evaluated for compliance. 
The technical completeness check is performed to 
ascertain that all elements required are in the dossiers 
and the registration fee is paid. Of the dossiers 
submitted, those on substances that are under product- 
and process-orientated research and developments 
(PPORD) passed more easily. A Technical 
Completeness Tool will be ready by the end of this 
year, so that companies can check completeness 
before submitting their dossiers. 
At present limited experience with dossier evaluation 
is available.  
ECHA has indicated that the main issues with the 
dossiers are related to substance identification (also of 
test material used in studies), inadequate justifications 
for waiving, poor quality of the robust study 
summaries in the dossier and non-compliance of 
studies with Good Laboratory Practice. It needs to be 
stressed that reasoning and documentation of 
arguments are essential points to satisfy the evaluation 
criteria of ECHA. 
Small and Medium Enterprises and 
REACH 
Awareness of REACH among Small and Medium 
Enterprises (SMEs) in Europe is increasing, but still 
companies find out that they ‘forgot’ to pre-register or 
failed to pre-register the correct substance. In 
addition, discussions about the status of products 
being an ‘article’ or a ‘formulation’ or a substance of 
UVCB
10 are ongoing.  
                                                      
10 Unknown or Variable Composition, Complex reaction 
products or Biological materials. 
SMEs are relatively strongly affected by the REACH 
regulation. In general, they lack human and financial 
resources to deal with REACH. Many SMEs are 
believed to be downstream users, but they might have 
additional roles (manufacturer/importer) as well. 
SMEs that are downstream users face complicated 
work when their use is not incorporated in the dossier 
submitted by their supplier. In that event, they have to 
compile their own dossier, which is highly specialist 
work. 
Costs/benefits 
No thorough cost-benefit analyses have recently been 
conducted on REACH. The available larger studies 
date from the period when early proposals on REACH 
were being discussed. REACH was altered 
considerably before the EU enacted it. Moreover, 
these studies were criticised as poorly documented 
and vague on the benefits.
11 REACH supports the 
protection of human health and environment, while 
enhancing free movement in the EU internal market 
and competitiveness. This ambition is very general 
and can only be supported. It is, however, difficult to 
substantiate. 
What valuable work there is on cost and benefits 
could not foresee the high numbers of (pre-) 
registrations now witnessed. Does this mean that the 
costs of REACH will increase proportionally or are 
the newly expected numbers of genuine registrations 
an over-estimation (and how large is this over-
estimation)? 
4.  REACH issues in the short run 
Many questions regarding the further development of 
the implementation of the REACH Regulation remain 
open. What can we expect during next year and how 
realistic are the deadlines? Will industry manage to 
comply with REACH? Will substances be phased-out 
(temporary) because of tight deadlines? Will REACH 
actually lead to innovation?  
Will REACH improve the transparency of the 
chemicals market? Will REACH indeed have a 
positive effect on human health and environment?  
Making the 2010 deadline 
Industry. The 2010-deadline is approaching rapidly. 
Many SIEFs do not function at all and others struggle 
with legal issues related to data- and cost-sharing. 
CEFIC has published a standard SIEF agreement to 
assist SIEFs in these matters. In view of the deadlines, 
agreement needs to be reached as soon as possible, 
since only then will the actual work begin. Activities 
are not limited to the building-up of the dossier, but 
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may well include complicated and time-consuming 
tests necessary to ascertain the properties as well as 
the development of exposure scenarios leading to safe 
use. Vertebrate tests that might be unavoidable 
include tests which take 6 to 9 months. Full 
development of an exposure scenario requires 
extensive discussions in the supply chain. This can 
last for many months. In short, registrants that do not 
obtain agreement in their SIEF may be running out of 
time to finish their dossiers before the deadlines. 
Guidance and tools. Work on generic exposure 
scenarios and electronic tools to assess such scenarios, 
is in a starting phase and needs to be completed before 
registrations can be done. Currently, updates of the 
guidance on registration, guidance on the guidance by 
authorities and industry organisations and explanatory 
notes are published on a regular basis, so that the final 
picture of the requirements for registration is being 
adapted all the time. Fortunately, very recently, new 
tools have become available.
12  
Number of substances. The number of substances to 
be registered by the 2010 deadline is now expected to 
amount to 55,000 (originally anticipated 3,000-4,000). 
It is not clear how realistic these figures are, but the 
increase augments the anticipated workload of both 
ECHA and the national authorities substantially. One 
wonders how ECHA will deal with this.  
In September 2009, the EP still had to rescue ECHA 
from an ill-considered EU budget cut by adding €4.5 
million for 2010, as fees will start coming in later. Of 
course this enormous number of substances also 
multiplies the efforts of the chemical industry. All this 
is likely to cause delays or to lead to difficult choices 
on prioritisation of substances within companies. 
Authorisation/replacement/innovation 
Substances that are considered of ‘very high concern’ 
will fall under authorisation, i.e. under very strict 
conditions will these substances be allowed to be used 
for a distinct period. Candidate substances for 
authorisation can be suggested by the EU member 
states. At this moment, 18 chemicals are present on 
the first candidate list of which seven have been 
prioritised to become subject to authorisation. An 
additional list of 15 proposed substances became 
available in early September 2009. The EU expects 
the candidate list to grow with 25 substances per year. 
Two non-official ‘black lists’ of substances of very 
high concern have been published by different NGOs: 
the SIN list (www.sinlist.org) and the TU list 
                                                      
12 For the specialists: a CSR10 tool, able to extract data 
from the technical dossier in IUCLID5 to the templates for 
the registration dossier, is the most important one. This tool 
will allow experts to work more efficiently to build up the 
dossiers. 
(www.osha.europa.eu). To include all 267-306 
substances on these lists in the candidate list will take 
more than ten years if the suggested 25 substances per 
year that can be handled is realistic. However, few 
observers expect that all substances on these lists will 
be subject to authorisation in the final analysis. On the 
other hand, these two lists do not contain all candidate 
substances for authorisation. Many of these will be 
identified during the REACH registration process 
when data on hazardous properties and exposure 
information will become available.  
The phase-out of substances of ‘very high concern’ 
and a proposal for replacement with less dangerous 
alternatives is part of the authorisation process. It 
seems unlikely that proper replacements can be found 
for all substances on the available lists within a 
defined period. Replacement and innovation can take 
years of research, entailing large investments. In 
certain industries, e.g. aerospace, replacement of a 
single substance in a product can take up to 10 years. 
Nevertheless, in the longer run, REACH will 
stimulate innovation and substitution. An additional 
problem in times of economic recession is the 
reduction of research budgets. There are examples of 
innovation induced by more strict EU legislation, e.g. 
on fluorinated compounds, but so far these successes 
are still rare.  
Supply chains 
It was expected that REACH would provide insights 
into the supply chains within the chemical industry, 
yielding concomitant advantages for control and safe 
use of chemicals. ‘Supply chains’, however, seldom 
exist. Companies are each others’ clients and/or 
suppliers and can have different roles in a single 
‘supply chain’. In most cases a ‘supply web’ is a more 
appropriate term. Supply webs do not stop at the EU 
borders and, without REACH obligations outside the 
EU, it is even more difficult to obtain insights into the 
webs abroad. Information exchange in supplier-client 
relationship is often likely to entail the exchange of 
confidential, critical business information on e.g. the 
composition of products or specific uses. This may be 
less of a problem in well-controlled supply chains like 
the automotive industry, but more so in loosely 
organised and complicated webs like the textile 
industry or the paint industry. In addition, in the 
absence of legal obligations, the willingness to share 
data is expected to be limited. Therefore, the 
expectations about a boost in transparency seem to 
have a weak basis in global business conduct. Many 
non-EU players will have insufficient awareness and 
complex supply webs are difficult to assess for 
enforcement purposes.  
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use (as far as it is more or less easy to assess). Beyond 
this, companies (down stream users) will be left on 
their own and asked to prepare their own dossiers. No 
doubt, this will affect especially the smaller 
companies with limited knowledge and resources.  
5.  Benefits and costs of REACH, once 
again 
The sharp contrast between the 2001 consensus 
among all stakeholders on the REACH principles and 
the bitter battle on the actual REACH proposal 
starting in May 2003 was caused by the deep concerns 
about the benefits and costs as well as their lopsided 
structure over time. The Commission’s RIA of 
REACH spent little effort and just a few lines (on the 
very last page) on an extremely rough ‘guesstimate’ of 
the benefits for public health, whilst declining to 
express any guess on environmental benefits. The 
Commission’s text gave the strong impression of 
doing the calculation of benefits as an afterthought. 
However, very considerable efforts were invested in 
order to come to grips with the expected costs, both 
direct and indirect. Thus, the REACH debate and 
decision-making process was deeply flawed from the 
beginning. ‘Better (EU) Regulation’ must be based on 
the benefits first. Why regulate if not for the benefits 
of health, environment as well as innovation?  
Indeed, the costs matter too, but they can be seen in 
perspective if, and only if, the benefits are at the very 
least well understood, if not (roughly) quantified over 
some reasonable range. One can suggest two main 
reasons why the benefits of REACH were difficult to 
come to grips with.  
First, the early design of REACH was based on the 
precautionary principle, but it was applied 
indiscriminately to all chemical substances instead of 
a subcategory where at least some suspicions might 
have been researched (as the precautionary principle 
suggests one should do; see European Commission, 
2000). With the wholesale application of the 
precautionary principle, one cannot – almost by 
definition – describe the scope and magnitude of the 
benefits due to a lack of knowledge. It is precisely in 
the disciplining of the application of the precautionary 
principle that ‘good regulation’ begins.  
Second, the benefits would only follow from a very 
lengthy period of testing and ‘registration’ based on 
risk assessment of all chemical substances. In other 
words, the benefits were to be reaped in the distant 
future whereas the costs had to be incurred upfront for 
many years. Such a time structure of benefits and 
costs is a nightmare for (elected) politicians. Although 
the chemical industry grossly exaggerated its lobbying 
on costs at first it remains undeniable that their 
concerns about the immediate costs and distant as well 
as unknown benefits were not without foundation. But 
the point about benefits can be sharpened still further: 
only the net benefits over and above those already 
gained from existing restrictions of chemicals should 
be counted. What (currently unrestricted) substances 
might yield these net benefits, was and is still 
unknown, but it would be pretty extreme to assume 
that their number would exceed (say) 2,000 or perhaps 
3,000, not anywhere near 30,000.  
Against this background it is of some interest to 
discuss the possible consequences of the ongoing 
implementation on benefits and costs.  
A well-performed investigation into the benefits 
seems essential to enhance the motivation to support 
the further implementation of REACH by industry, 
consumers and other stakeholders. 
REACH is unknown to the general public. No 
extensive television campaigns were initiated to let 
the European public know that this legislation is in 
place and that individual consumers have the right to 
ask questions about the safety of non-food products 
they are buying in retail shops. The legislation affects 
thousands of companies and millions of people.  
The consequences of REACH for the entire European 
(non-chemical) industry were poorly recognised and 
many questions remain unanswered. Help-desks are 
available and function well on standard questions, but 
remain silent on the more difficult ones. ECHA is 
trying hard to perform its enormous task properly, but 
the agency is still understaffed. Guidance documents 
of thousands of pages are produced, which now need 
explanatory fact sheets. The guidance is still 
incomplete and is updated almost on a daily basis. IT 
tools are available for some tasks, but others still need 
to be developed. For the management of the SIEFs, no 
legislative provisions are available. Industry 
competitors have to organise themselves and solve 
legal issues related to confidential business 
information and competition law, as well as IT 
solutions to communicate in SIEFs of thousands of 
members. How can industry keep track of all of this? 
Industry is responsible for the registration under 
REACH. A dossier will not be formally approved by 
the ECHA. There might be an evaluation that leads to 
questions and even to an authorisation, but in the end 
industry is responsible for the safe use of substances. 
This is a U-turn as compared to the previous system 
and is unique in the world. Industry cannot hide 
behind an approval, but faces full responsibility. This 
might prompt the phase-out of production or use of 
certain substances by the chemical industry on a 
voluntary basis. Companies assuming responsible care 
as a leading principle in their corporate strategy are 
expected to do this. In addition, there are reports on 
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countries, which is only a transfer of problems at the 
peril of others and not a sustainable solution.  
Regarding the costs, no new estimates are available at 
present. The number of substances to be registered 
turns out to be much larger then envisaged and this 
will influence the overall costs of REACH 
substantially. Every task related to registration is still 
a learning-by-doing experience and costs are difficult 
to estimate. SIEF duties take much time and 
significant resources. In times of economic recession 
it is difficult for companies to find and allocate 
resources to tasks that seem either poorly defined or 
changing in magnitude on a regular basis. There are 
already serious delays in many businesses and perhaps 
also inside ECHA. It seems almost impossible to keep 
to the extremely tight 2010 deadline (see Figure 2).  
Making choices seems unavoidable. Companies may 
decide to focus on fewer substances or take a less 
active role in the registration process.  
Resources are scarce and are sometimes found in-
house (production personnel filling in the dossiers?). 
One should not expect ECHA to postpone its 
deadlines. This is understandable, as the deadlines are 
included in the REACH Regulation. Amendments are 
not impossible,
13  but such changes would imply a 
time-consuming process. Therefore, the relevant 
query is which steps ECHA is willing to take without 
violating the REACH regulation. 
The lack of qualified resources to deal with REACH 
is another issue that causes delays. The numbers of 
toxicologists, eco-toxicologists, chemists and 
occupational hygienists with knowledge of REACH is 
limited and it is difficult to find these experts. Many 
consultancy companies have found the ‘world of 
REACH’, but experience difficulties hiring competent 
people. These employees need to have not only good 
knowledge of a huge regulation of considerable 
complexity and many technical annexes, but also the 
experience to solve complicated matters of hazard and 
risk assessment. REACH provides incentives to 
companies and testing houses to replace animal tests 
by non-animal testing, e.g. in vitro testing (testing in 
cells and tissues) and in silico testing (so-called 
QSARs, computer models simulating such tests (see 
Annex XI of the Regulation). These alternatives are in 
some cases more costly and time-consuming than the 
original tests. Worse, they are very often not yet 
officially validated.  
                                                      
13 Already today a number of amendments have been 
adopted by the Commission, such as those to Annexes IV 
and V, and later on to Annexes XI and XVII; a new EU 
regulation by the EU legislator on classification 
[1271/2008] is, so far, the only one involving the Council 
and the EP fully. 
Therefore, qualified toxicologists are indispensable to 
interpret the results of the alternatives and their 
usefulness as a substitute.  
Exemptions from REACH include the following: 
active substances in pesticides and biocides, co-
formulants in pesticides, cosmetics for human use 
only, veterinary and human medicinal products and 
several other classes. Nevertheless, REACH will 
influence the industries dealing with these regulated 
chemicals, e.g. raw materials and intermediates in the 
production process might be subject to REACH. For 
cosmetics, the situation is even more difficult. Most of 
the ingredients of cosmetics will need to be registered 
under REACH (although the consumer use of 
cosmetics is excluded in the REACH dossier) and thus 
will be tested in animals. The Cosmetic Directive,
14 
however, no longer allows animal testing on 
ingredients (first deadline March 2009, second 2013).  
This would mean that many substances tested under 
REACH will no longer be permitted as ingredient of 
cosmetics. This might well entail drastic 
consequences for the EU cosmetics industry. 
6. Conclusions 
The implementation of REACH was always expected 
to be a huge effort on the part of ECHA and business 
throughout the value chain, inside as well as outside 
the EU, chemical companies as well as downstream 
users. However, it now turns out to be a process with 
still more complications and hiccups due to 
unforeseen details and lingering uncertainties with 
respect to some technical aspects. The SIEFs lack an 
overall ‘governance’ system, which should preferably 
be run by ECHA, as this would provide badly needed 
certainty and early information at the Agency level 
about the weaknesses and incipient failures of (many) 
SIEFs. The hiccups have the unfortunate effect of 
delaying or overburdening the current preparations for 
the December 2010 deadline.  
The 2010 deadline appears to be too tight now that 
difficulties and uncertainties have emerged or lingered 
during the actual practice of implementation. Creative 
solutions for bottlenecks are essential. Current 
indications are that a very considerable number of 
SMEs and importers will simply not be capable of 
registering in time or will submit with gaps and 
omissions causing other delays. The authors would 
not expect ECHA to be able to answer all the 
questions raised, but some pragmatic ideas on how to 
meet the deadlines are nonetheless urgently required. 
The authorities in the capitals, Brussels and Helsinki 
                                                      
14 The 1976 Directive (76/768/EEC) is under review. 
However, the seventh amendment to Directive 2003/15 
seeks to phase out animal testing. Detailed timelines can be 
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cannot close their eyes to what is (not) happening in 
the REACH process and merely state that the 
deadlines will not be postponed. Many examples of 
how to work on REACH in time and cost-efficient 
and effective ways are available. These can be most 
helpful for others, but it takes learning and 
organisational time to initiate the effective and fully-
compliant implementation in the complex REACH 
environment. Can one really pursue the course when 
such large numbers of ‘drop-outs’ are at risk? A slight 
delay in the start of the REACH train can be justified 
in order to allow everyone to catch it in the end. 
However, timing is not the only problem. Questions 
concerning such issues as enforcement, the processes 
in supply chains, or better ‘supply webs’ and costs and 
benefits are perhaps even more important.  
Enforcement will differ between EU member states, 
both with respect to controls and to the penalties for 
non-compliance. The Forum has only an advisory 
status and cannot impose rules or harmonise 
approaches. The chain of REACH is as strong as its 
weakest link and enforcement might be the weakest 
link. It would be unacceptable if industrial activities 
or ORs are moved to EU countries known for their lax 
enforcement policy. The notion of supply chains 
proves to be somewhat academic for REACH 
obligations which are demanding. We employ the 
term ‘supply webs’ which exemplifies the diverse and 
multi-functional links between chemical companies in 
various layers of value-added as well as downstream 
users. No one can know for sure how (im)practical the 
REACH obligations of passing on sufficient and well-
structured information on substances will be outside 
the traditional bounds of the chemical sector and 
outside the EU more generally. But for numerous EU 
companies, it might put their business at risk even 
though their efforts in obtaining the relevant 
information have been energetic and sincere. 
Finally, the lingering problems – not to speak of the 
unexpectedly high numbers of pre-registrations – tend 
to further raise the unprecedented upfront costs of 
REACH. These increased costs and uncertainties have 
to be appreciated given the absence (so far) of any 
new indications of benefits of a similar magnitude to 
European society. The authors therefore urge a much 
closer attention to what benefits might actually result 
from REACH. Good regulation requires first and 
above all, a solid understanding of the benefits of 
regulation. Otherwise, why regulate? And why at such 
huge up-front costs? We do appreciate the recent 
REACH Baseline study as a worthwhile attempt to 
begin monitoring whether indeed REACH will yield 
the benefits the EU has long hoped for (see 
EUROSTAT, 2009). 
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